Sustained release compositions using wax-like materials
Sustained release spherical or non-spherical pellets comprising (a) an active ingredient (b) a wax-like agent, and (c) a spheronizing agent are provided. Oral dosage forms comprising the pellets and methods for preparing and using such pellets and dosage forms are also provided.
1. A composition comprising:
(a) an active ingredient, wherein the active ingredient is glucosamine or a pharmaceutically acceptable salt thereof;
(b) from about 5% to about 40% of a wax-like agent, wherein the wax-like agent is hydrogenated vegetable oil; and
(c) from about 5% to about 40% of a spheronizing agent, wherein the ratio of the wax-like agent to the spheronizing agent is in a range from about 3:1 to about 1:14 by weight and; wherein the spheronizing agent is a member selected from the group consisting of microcrystalline cellulose and a combination of microcrystalline cellulose and pregelatinized starch, and wherein the spheronizing agent together with the active ingredient and the wax-like agent form a cohesive plastic mass that is malleable and is subsequently extruded and spheronized;
wherein (i) the composition is in the form of pellets, without a sustained release barrier coating, wherein said pellets have an average diameter of about 0.1 mm to about 3 mm in size and are either spherical or cylindrical in shape; (ii) the composition has an in vitro dissolution rate of the active ingredient measured by standard USP basket method of about 10% to about 60% of the active ingredient released after 1 hour;
about 20% to about 70% of the active ingredient released after 2 hours;
about 30% to about 80% of the active ingredient released after 4 hours;
about 40% to about 90% of the active ingredient released after 8 hours;
about 50% to about 100% of the active ingredient released after 12 hours; and (iii) the in vitro dissolution rate of the active ingredient does not require the presence of a sustained release barrier coating on the pellets.
2. The composition of claim 1 , wherein the pellets are spherical.
3. The composition of claim 1 , wherein the pellets are cylindrical.
4. The composition of claim 1 , comprising: from about 5% to about 90% of the active ingredient, wherein the active ingredient is glucosamine or a pharmaceutically acceptable salt thereof.
5. The composition of claim 1 , further comprising one or more inactive ingredients.
6. The composition of claim 5 , wherein the one or more inactive ingredient is selected from the group consisting of a binder, antioxidant, or colorant.
7. The composition of claim 5 , wherein the one or more inactive ingredients are present at the total concentration from about 0.01% to about 5.0% based on the pellet weight.
8. The composition of claim 1 , comprising:
(a) from about 45% to about 85% of glucosamine or a pharmaceutically acceptable salt thereof;
(b) from about 5% to about 30% of hydrogenated vegetable oil;
(c) from about 5% to about 20% of microcrystalline cellulose; and from about 1% to about 10% pregelatinized starch.
9. The composition of claim 1 , wherein the pellets are coated.
10. The composition of claim 2 , wherein the average diameter of the spherical pellets are about 0.5 mm to about 1.5 mm.
11. The composition of claim 1 , wherein the hydrogenated vegetable oil is hydrogenated cottonseed oil.
12. The composition of claim 1 , wherein the spheronizing agent is microcrystalline cellulose.
13. A dosage form comprising the composition of claim 1 .
14. The dosage form of claim 13 , further comprising an inactive ingredient selected from the group consisting of flavorants, suspending agents, anticaking agents, fillers, sweeteners, and lubricants.
15. The dosage form of claim 13 , wherein the dosage form further comprises water and is in the form of an oral suspension.
16. The dosage form of claim 13 packaged in a bottle, packet, pouch, sachet, or capsule.
17. The dosage form of claim 13 , wherein the dosage form, upon oral administration to a patient in need thereof, provides a plasma concentration of the active agent at or above its minimum effective concentration for at least 12 hours.
18. The dosage form of claim 13 , wherein the dosage form, upon oral administration to a patient in need thereof, provides a plasma concentration of the active agent at or above its minimum effective concentration for a period of time that is at least 2 times of that of an immediate release formulation administered at a standard dose.
19. The dosage form according to claim 13 , wherein dosage form is suitable for administration to a patient in need thereof once or twice per day.